From studying the human genome, to analyzing the way proteins are encoded, or monitoring RNA expression, researchers are rapidly gaining a far richer understanding of the complex genetic and cellular mechanisms that underpin dementia. But there’s a catch: While new technologies are revealing myriad avenues for Alzheimer’s research, it’s impossible to know in advance which research pathways will lead to effective treatments.
Decentralized trials: FDA lays out its thinking in new draft guidance
Avadel Pharmaceuticals notched an FDA approval for narcolepsy drug Lumryz on Monday following a multi-year court battle with Jazz Pharmaceuticals. Jazz was forced to delist
May 3, 2023